Search

Your search keyword '"Richard M. Stone"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Richard M. Stone" Remove constraint Author: "Richard M. Stone"
219 results on '"Richard M. Stone"'

Search Results

1. Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen

2. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

3. FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity

4. Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement

5. A precision medicine classification for treatment of acute myeloid leukemia in older patients

7. Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies

8. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

9. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia

11. Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia

12. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

13. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

14. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

15. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

16. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

18. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

19. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches

20. Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration

22. Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

23. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

24. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

25. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

26. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia

27. MEN1 mutations mediate clinical resistance to menin inhibition

28. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention

29. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

30. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

32. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

33. Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

34. Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

35. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

37. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition

38. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

39. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax

40. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

41. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

42. Association of social deprivation with survival in younger adult patients with AML: an Alliance study

44. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

45. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials

46. Supplementary Figure from The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation

47. Supplementary Table 3 from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition

48. Data from BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes

49. Supplementary Table 1 from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition

50. Supplementary Figure from BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes

Catalog

Books, media, physical & digital resources